← Back to Search

DaTscan for Parkinson's Disease (PPMI Trial)

Phase 2
Waitlist Available
Research Sponsored by Ken Marek, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Not expected to require PD medication with at least 6 months from Baseline.
• Male or female age 30 years or older at Screening.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study intervals ranging from 3 months to 156 months
Awards & highlights

PPMI Trial Summary

This trial will compare the progression of Parkinson's disease in patients to healthy controls, and between different subtypes of Parkinson's disease. The goal is to identify clinical, imaging, and biologic markers of Parkinson's disease progression to help guide future clinical trials of disease-modifying therapies.

PPMI Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
• Age 30 years or older.
Select...
You are 30 years or older at the time of PD diagnosis.

PPMI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study intervals ranging from 3 months to 156 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and study intervals ranging from 3 months to 156 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Rates of Change
Secondary outcome measures
Comparison between Rates of Change
Exploratory Analysis
Predictive Value
+2 more

PPMI Trial Design

1Treatment groups
Experimental Treatment
Group I: Datscan SPECT ImagingExperimental Treatment1 Intervention
Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ioflupane I-123
FDA approved

Find a Location

Who is running the clinical trial?

Ken Marek, MDLead Sponsor
Institute for Neurodegenerative DisordersOTHER
48 Previous Clinical Trials
12,062 Total Patients Enrolled
Kenneth L Marek, MDStudy ChairInstitute for Neurodegenerative Disorders
5 Previous Clinical Trials
505,292 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
University of Rochester
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
~65 spots leftby Mar 2025